Key Points
- Director Luke Evnin sold a total of about 440,714 shares of Werewolf Therapeutics between Dec. 22 and Jan. 7, generating roughly $279,534 in proceeds; after the Jan. 5 filing he still directly owned 2,453,919 shares (~$1.57M in value).
- Stock and analyst snapshot: HOWL trades around $0.64 (50‑day MA $0.92, 200‑day MA $1.26) with a $31.1M market cap and a 52‑week range of $0.56–$2.38; the consensus rating is Hold (average target $3.75) amid several recent downgrades.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,378 shares of the firm's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $0.64, for a total transaction of $11,761.92. Following the completion of the transaction, the director directly owned 2,453,919 shares in the company, valued at $1,570,508.16. This represents a 0.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Luke Evnin also recently made the following trade(s):
- On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $7,625.60.
- On Tuesday, January 6th, Luke Evnin sold 40,761 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total value of $26,494.65.
- On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
- On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total value of $15,476.44.
- On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $21,256.67.
- On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total transaction of $66,249.66.
- On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $22,448.16.
- On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total transaction of $10,601.50.
- On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
- On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $40,921.83.
Werewolf Therapeutics Price Performance
Shares of NASDAQ:HOWL opened at $0.64 on Thursday. The firm's 50 day moving average is $0.92 and its two-hundred day moving average is $1.26. The firm has a market capitalization of $31.13 million, a P/E ratio of -0.40 and a beta of 0.77. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a 52 week low of $0.56 and a 52 week high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.03. Analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on HOWL. Citizens Jmp cut shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, December 19th. Wedbush downgraded shares of Werewolf Therapeutics from an "outperform" rating to a "neutral" rating and set a $1.00 price target on the stock. in a research report on Friday, December 19th. HC Wainwright decreased their price objective on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a "buy" rating for the company in a report on Friday, December 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Zacks Research downgraded Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 21st. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics presently has a consensus rating of "Hold" and an average price target of $3.75.
Check Out Our Latest Stock Analysis on HOWL
Institutional Trading of Werewolf Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in HOWL. Susquehanna International Group LLP lifted its stake in Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company's stock valued at $183,000 after purchasing an additional 13,439 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Werewolf Therapeutics in the third quarter valued at $304,000. Vanguard Group Inc. lifted its position in shares of Werewolf Therapeutics by 8.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock valued at $2,774,000 after acquiring an additional 109,796 shares during the last quarter. Bridgeway Capital Management LLC boosted its stake in shares of Werewolf Therapeutics by 157.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company's stock worth $111,000 after acquiring an additional 62,414 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock worth $2,321,000 after acquiring an additional 25,882 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors.
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
